CD28 superagonists: Mode of action and therapeutic potential
- 1 August 2005
- journal article
- review article
- Published by Elsevier in Immunology Letters
- Vol. 100 (1) , 21-28
- https://doi.org/10.1016/j.imlet.2005.06.012
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- T Cell Receptor-Independent Basal Signaling via Erk and Abl Kinases Suppresses RAG Gene ExpressionPLoS Biology, 2003
- Role of CD28 co-stimulation in generation and maintenance of virus-specific T cellsInternational Immunology, 2002
- The B7–CD28 superfamilyNature Reviews Immunology, 2002
- Immunopathology of interleukin (IL) 2-deficient mice: thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene.The Journal of Experimental Medicine, 1995
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995
- Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartmentImmunity, 1995
- Deregulated T Cell Activation and Autoimmunity in Mice Lacking Interleukin-2 Receptor βScience, 1995
- The role of p21ras in CD28 signal transduction: triggering of CD28 with antibodies, but not the ligand B7-1, activates p21ras.The Journal of Experimental Medicine, 1994
- T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor.The Journal of Experimental Medicine, 1992
- A Cell Culture Model for T Lymphocyte Clonal AnergyScience, 1990